Full Generic Medicine Info
Dosage/Direction for Use

Adult: 150 mg once daily, may increase to 300 mg once daily if needed. Patient w/ intravascular volume depletion: Initially, 75 mg once daily.
Elderly: >75 yr Initially, 75 mg once daily.
Renal impairment: Haemodialysis: Initially, 75 mg once daily.

Diabetic nephropathy in Type 2 diabetes mellitus
Adult: Initially, 150 mg once daily, may increase to 300 mg once daily if needed.
May be taken with or without food.
Concomitant use w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min). Pregnancy.
Special Precautions
Patients w/ unilateral or bilateral renal artery stenosis, depletion of intravascular volume, aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy. Renal impairment. Lactation. Monitoring Parameters Monitor renal function periodically; electrolytes and serum creatinine levels.
Adverse Reactions
Diarrhoea, fatigue, dyspepsia or heartburn, dizziness, orthostatic hypotension, nausea, vomiting, musculoskeletal pain, thrombocytopaenia, hyperkalaemia, elevated serum creatinine.
Symptoms: Hypotension, tachycardia, bradycardia. Management: Symptomatic and supportive treatment. Induction of emesis and/or gastric lavage. Activated charcoal may also be helpful.
Drug Interactions
May antagonise hypotensive effect and increase risk of nephrotoxicity w/ NSAIDs. May increase serum lithium levels and toxicity. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.
Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
Irbesartan is an angiotensin II receptor antagonist. It blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by binding to AT1 receptors.
Onset: 1-2 hr.
Duration: >24 hr.
Absorption: Rapidly absorbed from the GI tract. Bioavailability: 60-80%. Time to peak plasma concentration: 1.5-2 hr.
Distribution: Volume of distribution: 53-93 L. Plasma protein binding: Approx 96%.
Metabolism: Undergoes hepatic metabolism via CYP2C9 isoenzyme to inactive metabolites.
Excretion: Via bile and urine (as unchanged drug and metabolites); urine (approx 20%, <2% as unchanged drug). Terminal elimination half-life: Approx 11-15 hr.
Oral: Store between 15-30°C.
CIMS Class
Angiotensin II Antagonists
ATC Classification
C09CA04 - irbesartan ; Belongs to the class of angiotensin II antagonists. Used in the treatment of cardiovascular disease.
Disclaimer: This information is independently developed by CIMS based on irbesartan from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in